BPA
ORIC icon

Beacon Pointe Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Beacon Pointe Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,040
Closed -$44K – 1044
2022
Q2 		$44K Buy
+10,040
New +$40.1K ﹤0.01% 1025

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Beacon Pointe Advisors's ORIC Position: Q3 2022 in Review

Beacon Pointe Advisors sold out of Oric Pharmaceuticals (ORIC) in Q3 2022, closing a stake of 10,040 shares — an estimated $44K sold.

Beacon Pointe Advisors first reported a position in ORIC in Q2 2022 and held it in 1 quarter. The position peaked at $44K in Q2 2022. 76 funds tracked by Wall St. Rank hold ORIC as of Q3 2022.

  • Beacon Pointe Advisors reported no remaining Oric Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Beacon Pointe Advisors sold 10,040 Oric Pharmaceuticals shares in Q3 2022, an estimated $44K.
  • Beacon Pointe Advisors first reported a position in Oric Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Beacon Pointe Advisors's Oric Pharmaceuticals position peaked at $44K in Q2 2022.
  • 76 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2022.

Based on Beacon Pointe Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.